You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金對中藥及醫藥股投資評級及目標價(表)
中金上週五(12月31日)發表報告,列出中藥及內地醫藥股投資評級及目標價: 股份│投資評級│目標價(港元) 白雲山(00874.HK)│跑贏行業│25元 同仁堂科技(01666.HK)│跑贏行業│7.1元 國仁堂國藥(03613.HK)│跑贏行業│13.3元 中國中藥(00570.HK)│跑贏行業│5.05元 阿裏健康(00241.HK)│跑贏行業│102.4元 京東健康(06618.HK)│跑贏行業│10.9元 華潤醫藥(03320.HK)│跑贏行業│5.42元 ------------------------------------------------------ 股份│預測2022年市盈率 白雲山│7.5倍 同仁堂科技│13.8倍 國仁堂國藥│14.7倍 中國中藥│9.7倍 華潤醫藥│5.1倍
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account